Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and without lipid lowering therapy - NAFLD

• Conditions: onalcoholic fatty liver disease (NAFLD) is a potentially progressive liver disease, leading to cirrhosis in up to 26% of affected patients and rarely hepatocellular carcinoma. Several studies have linked NAFLD to the metabolic syndrome even in non-obese patients with normal glucose tolerance.

• Registration Number: EUCTR2005-003231-46-AT
• Lead Sponsor: Dept of Internal Medicine IV, Med Uni Vienna

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-30
• Last Update Posted: 10 July 2015

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

•Patients with elevated liver enzymes and NAFLD (=33% hepatic steatosis) on liver histology in whom other causes of liver disease have been excluded.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•viral hepatitis (A, B, C)
•autoimmune, genetic, cholestatic liver diseases
•consumption of >140 grams of alcohol per week
•regular exercise training (=3 times per week) before begin of the study
•pregnancy and lactation
•known hypersensitivity to Ezetimibe
•Patients currently taking lipid lowering agents
-contraindications to MR-Spectroscopy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified